Akari Therapeutics (AKTX) Share-based Compensation (2012 - 2026)
Akari Therapeutics recorded quarterly Share-based Compensation of $305000.0 in Q1 2026, down 89.35% quarter-over-quarter from $2.9 million in Q4 2025, and down 69.95% year-over-year from $1.0 million in Q1 2025.
Akari Therapeutics' Share-based Compensation history runs 14 years deep, the most recent figure standing at $305000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation fell 69.95% year-over-year to $305000.0; the TTM figure through Mar 2026 stood at $4.6 million (up 361.82% YoY), while the FY2025 annual figure was $2.9 million, up 966.42% from the prior year.
- Share-based Compensation came in at $305000.0 for Q1 2026 at Akari Therapeutics, down from $2.9 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.9 million in Q4 2025 to a low of -$718000.0 in Q4 2024.
- A 5-year average of $481979.5 and a median of $304000.0 in 2023 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation plunged 336.18% in 2024 and soared 498.75% in 2025, its largest moves.
- Akari Therapeutics' Share-based Compensation stood at $122856.0 in 2022, then jumped by 147.44% to $304000.0 in 2023, then slumped by 336.18% to -$718000.0 in 2024, then jumped by 498.75% to $2.9 million in 2025, then plunged by 89.35% to $305000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $305000.0, $2.9 million, and $685000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 87.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 305,000.00 |
| Mar 31, 2026 | 305,000.00 |
| Dec 31, 2025 | -2.39 Mn |
| Dec 31, 2025 | -2.39 Mn |
| Sep 30, 2025 | 685,000.00 |
| Sep 30, 2025 | 685,000.00 |
| Jun 30, 2025 | 719,000.00 |
| Jun 30, 2025 | 719,000.00 |
| Mar 31, 2025 | 1.02 Mn |
| Mar 31, 2025 | 1.02 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | 248,000.00 |
| Sep 30, 2024 | 248,000.00 |
| Jun 30, 2024 | 445,000.00 |
| Jun 30, 2024 | 445,000.00 |
| Mar 31, 2024 | 296,000.00 |
| Mar 31, 2024 | 296,000.00 |
| Dec 31, 2023 | -704,000.00 |
| Dec 31, 2023 | -704,000.00 |
| Sep 30, 2023 | 305,000.00 |
| Sep 30, 2023 | 305,000.00 |
| Jun 30, 2023 | 276,000.00 |
| Jun 30, 2023 | 276,000.00 |
| Mar 31, 2023 | 265,000.00 |
| Mar 31, 2023 | 265,000.00 |
| Jun 30, 2022 | 122,856.00 |
| Jun 30, 2022 | 122,856.00 |
| Mar 31, 2022 | 98,836.00 |
| Mar 31, 2022 | 98,836.00 |
| Dec 31, 2021 | -237.60 Bn |
| Dec 31, 2021 | -237.60 Bn |
| Sep 30, 2021 | 237.60 Bn |
| Sep 30, 2021 | 237.60 Bn |
| Jun 30, 2021 | 82,102.00 |
| Jun 30, 2021 | 82,102.00 |
| Mar 31, 2021 | 84,892.00 |
| Mar 31, 2021 | 84,892.00 |
| Dec 31, 2020 | -244.94 Bn |
| Dec 31, 2020 | -244.94 Bn |
| Sep 30, 2020 | 244.94 Bn |
| Sep 30, 2020 | 244.94 Bn |
| Jun 30, 2020 | -100.50 Bn |
| Jun 30, 2020 | -100.50 Bn |
| Mar 31, 2020 | 100.50 Bn |
| Mar 31, 2020 | 100.50 Bn |
| Dec 31, 2019 | 105,941.00 |
| Dec 31, 2019 | 105,941.00 |
| Sep 30, 2019 | 137,385.00 |
| Sep 30, 2019 | 137,385.00 |
| Jun 30, 2019 | 409,622.00 |
| Jun 30, 2019 | 409,622.00 |
| Mar 31, 2019 | 394,439.00 |
| Mar 31, 2019 | 394,439.00 |
| Dec 31, 2018 | 417,336.00 |
| Dec 31, 2018 | 417,336.00 |
| Sep 30, 2018 | 403,769.00 |
| Sep 30, 2018 | 403,769.00 |
| Jun 30, 2018 | 351,981.00 |
| Jun 30, 2018 | 351,981.00 |
| Mar 31, 2018 | 475,958.00 |
| Mar 31, 2018 | 475,958.00 |
| Dec 31, 2017 | 505,938.00 |
| Dec 31, 2017 | 505,938.00 |
| Sep 30, 2017 | 481,337.00 |
| Sep 30, 2017 | 481,337.00 |
| Jun 30, 2017 | 824,549.00 |
| Jun 30, 2017 | 824,549.00 |
| Mar 31, 2017 | 923,122.00 |
| Mar 31, 2017 | 923,122.00 |
| Dec 31, 2016 | 1.29 Mn |
| Dec 31, 2016 | 1.29 Mn |
| Sep 30, 2016 | 1.02 Mn |
| Sep 30, 2016 | 1.02 Mn |
| Jun 30, 2016 | 805,406.00 |
| Jun 30, 2016 | 805,406.00 |
| Mar 31, 2016 | 816,805.00 |
| Mar 31, 2016 | 816,805.00 |
| Dec 31, 2015 | 213,804.00 |
| Dec 31, 2015 | 213,804.00 |
| Sep 30, 2015 | 826,062.00 |
| Sep 30, 2015 | 826,062.00 |
| Jun 30, 2014 | 156,000.00 |
| Jun 30, 2014 | 156,000.00 |
| Mar 31, 2014 | 195,000.00 |
| Mar 31, 2014 | 195,000.00 |
| Dec 31, 2012 | 394,000.00 |
| Dec 31, 2012 | 394,000.00 |